- How Far Can the Body Go? Scientists Find the Ultimate Limit of Human Endurance SciTechDaily
- Even for elite athletes, the body’s metabolism has its limits Science News
- How to Push Your Metabolic Ceiling – and Burn More Calories Without…
Blog
-
How Far Can the Body Go? Scientists Find the Ultimate Limit of Human Endurance – SciTechDaily
-

PUBG and InZoi publisher Krafton declares itself an “AI-first company”, “placing AI at the centre of problem solving”
PUBG and Subnautica 2 publisher Krafton has declared itself an “AI-first company”, announcing a move to “place AI at the centre of problem solving” via a “complete” company reorganisation.
The megacorp outlined its “transition to…
Continue Reading
-

Novartis Avidity Biosciences in talks
Signage for Novartis AG at a building in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023.
Bloomberg | Bloomberg | Getty Images
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported, citing a person familiar with the matter.
A deal could be announced as early as Sunday, the report said.
Novartis and Avidity didn’t immediately respond to CNBC’s requests for comment.
Avidity specializes in developing an innovative class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates. RNA-based therapeutics are a relatively new class of medications that work by altering how genes are expressed to treat or prevent diseases.
The reported discussions come as Novartis ramps up its research and development division. The company earlier this year pledged to invest $23 billion to build out its U.S.-based infrastructure, which includes plans to construct a second R&D hub in San Diego.
The company has also struck two key deals with Anthos Therapeutics and Regulus Therapeutics this year to boost its development and manufacturing of cardiovascular and kidney disease drugs.
Avidity shares closed at $49.15 on Friday. The stock, which has a market capitalization of roughly $7.2 billion, is up nearly 70% since the beginning of the year. Novartis shares closed at $130.36 on Friday.
Read the complete Bloomberg News report here.
Continue Reading
-

Radiohead’s Thom Yorke says he won’t play Israel under Netanyahu, but slams BDS movement
Radiohead frontman Thom Yorke told the UK’s Sunday Times that he won’t play in Israel again while Prime Minister Benjamin Netanyahu is in power, and that Israel should not be part of Eurovision, while also criticizing pro-Palestinian…
Continue Reading
-
Fonseca's rise continues, wins biggest career title in Basel – ATP Tour
- Fonseca’s rise continues, wins biggest career title in Basel ATP Tour
- Joao Fonseca vs Jaume Munar Preview: Head-to-Head and Prediction for Swiss Indoors Basel 2025 PFSN
- Tennis, ATP – Swiss Indoors 2025: Davidovich Fokina takes out Humbert
Continue Reading
-

Wan 2.5 vs. Wan 2.2: Inside the Next Leap of AI Video Generation on WanVideo.co
The rapid evolution of AI video generation has reshaped how creators, educators, and marketers produce visual content. In this fast-moving landscape, models like Wan 2.2 laid the foundation for prompt-based video creation —…
Continue Reading
-

Radiohead’s Thom Yorke says would not now play in Israel
Radiohead frontman Thom Yorke has said in a British newspaper interview he would not now perform in Israel, eight years after the band defied pro-Palestinian activists to play a Tel Aviv gig.
“Absolutely not. I wouldn’t want to be 5,000 miles…
Continue Reading
-

Can AMD’s Rally Continue After a 58.6% Surge in the Past Month?
If you are trying to decide what to do with Advanced Micro Devices stock, you are definitely not alone right now. The past few months have been a wild ride for AMD, giving investors plenty to cheer about. After a steady upward climb, the stock closed at $252.92, with a stunning 109.7% gain year-to-date and an eye-popping 58.6% pop just in the last month. That sort of momentum naturally has everyone wondering: is there more room to run, or is this as good as it gets?
Much of this excitement traces back to the growing market buzz around AI computing, where AMD has been grabbing headlines thanks to both its latest hardware launches and fresh partnerships with big players in cloud infrastructure. Though the AI story is driving a lot of expectations, the market seems to be constantly re-evaluating AMD’s competitive positioning and its ability to keep growing as more players rush in. Notably, the 8.5% gain over the past week hints at renewed confidence in the company’s prospects compared to rivals.
But hype alone does not tell the full story. If you are trying to make a level-headed decision, valuations matter. Looking under the hood, AMD’s current value score sits at 2 out of 6, meaning the stock is flagged as undervalued in just two checks out of the six most common methods. That is neither a screaming deal nor a red flag; instead, it calls for a deeper look at how AMD stacks up across key metrics.
Let’s dig into those valuation approaches and see what each can (and cannot) reveal, because as you will see, there is an even better way to make sense of AMD’s worth that many investors overlook.
Advanced Micro Devices scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future free cash flows and discounting them back to today’s dollars. This approach gives investors a sense of what the business is fundamentally worth based on its ability to generate cash over time.
For Advanced Micro Devices, the DCF model starts with its latest reported Free Cash Flow of $4.1 Billion. Analyst estimates provide projections out to 2029, forecasting that AMD could generate as much as $18.7 Billion in free cash flow by that year. After five years, additional annual projections are extended through 2035, all converted into today’s terms using a required rate of return.
Based on these assumptions and projections, the estimated DCF fair value for AMD is $165.73 per share. With the current share price at $252.92, this model implies the stock is trading at about a 52.6% premium to its intrinsic value. This suggests AMD appears substantially overvalued based on this cash flow methodology, even when factoring in robust long-term growth.
Continue Reading
-

Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
Cytokines are believed to play a key role in treatment resistance in patients with
ovarian cancer , according to a new review article published in theInternational Journal of Cancer , but the exact role and mechanisms behind it have remained…Continue Reading
-
This Common Organism Could Survive on Mars – SciTechDaily
- This Common Organism Could Survive on Mars SciTechDaily
- Baker’s yeast has the resilience to withstand Martian environment: Study The Hindu
- IISc study suggests yeast could be first Earth organism to live on Mars Moneycontrol
- Survival of the…
Continue Reading